Welcome to our dedicated page for Tectonic Therapeutic SEC filings (Ticker: TECX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to decode Tectonic Therapeutic’s dense SEC paperwork? Clinical-stage biotech reports are packed with GPCR science, trial data tables and dilution disclosures that can bury the R&D story investors need. Each 10-K or S-1 from Tectonic Therapeutic (TECX) runs hundreds of pages, while Form 4 insider trades may hint at management’s confidence long before headline news.
Stock Titan solves that problem. Our AI engine turns every Tectonic Therapeutic quarterly earnings report 10-Q filing, 8-K material events, and proxy statement executive compensation section into plain-English highlights you can scan in minutes. Receive real-time alerts the moment a Tectonic Therapeutic Form 4 insider transactions real-time update posts to EDGAR, jump straight to cash-runway notes, or view a chart that links R&D spend to milestone payments. Natural-language answers like “understanding Tectonic Therapeutic SEC documents with AI” appear beside each section so you never hunt for definitions again.
Whether you’re tracking a shelf registration, analysing Tectonic Therapeutic earnings report filing analysis, or comparing option grants from the Tectonic Therapeutic proxy statement executive compensation, our platform keeps every document in context. You can even bookmark “Tectonic Therapeutic annual report 10-K simplified” or monitor “Tectonic Therapeutic insider trading Form 4 transactions” to catch buying or selling trends before the market reacts. All filings—10-K, 10-Q, 8-K, S-1, DEF 14A—arrive within seconds and are paired with expert commentary, giving you the clarity to act, not just read.
Tectonic Therapeutic, Inc. (TECX) – Form 4 filing overview
CEO and Director Alise Reicin reported a single administrative transaction dated 06/20/2025. The filing shows 859 common shares disposed (Code F) at a price of $19.81 per share. The shares were withheld by the issuer exclusively to cover tax obligations triggered by the vesting and settlement of restricted stock units granted on 12/04/2024. No open-market purchase or sale occurred.
After the transaction, Reicin’s beneficial ownership stands at 213,485 shares held directly and 124,530 shares held indirectly through the Reicin-Boiarsky Family Trust, where her spouse is co-trustee. No derivative securities were exercised, acquired, or disposed of, and there are no new option grants or expirations disclosed.
The reported disposal represents less than 0.3% of Reicin’s total reported holdings, indicating a routine, non-material adjustment rather than a directional change in insider sentiment.
FAQ
What is the current stock price of Tectonic Therapeutic (TECX)?
What is the market cap of Tectonic Therapeutic (TECX)?
